Navigation Links
Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
Date:6/27/2011

PARSIPPANY, N.J., June 27, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that it has been included in the Russell 3000® Index following Russell Investments' reconstitution of its comprehensive set of U.S. and global equity indexes on June 24, 2011.

The Russell 3000 Index measures the performance of the 3,000 largest U.S. companies representing approximately 98 percent of the investable U.S. equity market. According to Russell Investments, the Russell 3000 Index is constructed to provide a comprehensive, unbiased and stable barometer of the broad market and is completely reconstituted annually to ensure new and growing equities are reflected. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 also serves as the U.S. component to the Russell Global Index.

For more information or to view the full Russell 3000® Index, please visit http://www.russell.com/Indexes/.

About Pacira

Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, manufacture and commercialization of novel pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. In December 2010, Pacira announced that its New Drug Application (NDA) for EXPAREL, the company's most advanced investigational product candidate, had been accepted for filing by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 28, 2011 for the review of the EXPAREL NDA. EXPAREL is a bupivacaine-based product and has completed extensive Phase 3 clinical development for postoperative analgesia by infiltration. EXPAREL consists of bupivacaine encapsulated in DepoFoam, which is designed to address the limitations of widely used medications by enhancing their dosing and/or administration profile. Additional information about Pacira is available at www.pacira.com.

Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about EXPAREL's potential, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the timing of, and our ability to obtain regulatory approval of EXPAREL; the timing of our anticipated commercial launch of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our commercialization and marketing capabilities; and other factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2010, and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts:

James S. Scibetta
Chief Financial Officer
Pacira Pharmaceuticals, Inc.
(973) 254-3570

Jennifer Beugelmans
Vice President, Investor Relations
Pure Communications, Inc.
(646) 596-7473


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Research and Markets has announced the addition of the ... their offering. ... The interventional radiology products market is expected to reach USD 8.02 ... CAGR of 4.8%. This market is segmented based on type, procedure, ... of this market are rising incidence of chronic diseases, rising geriatric ...
(Date:1/23/2017)... , Jan. 23, 2017 LifeVac, the ... a blocked airway and prevented choking deaths, welcomes ... advocate to the LifeVac team as Official Spokesperson. ... join the LifeVac team," said Arthur Lih , ... to represent LifeVac and his mission to raise awareness ...
(Date:1/23/2017)... TORONTO , Jan. 23, 2017 ... both 510(k) clearance from the U.S. Food and ... from Health Canada enabling the North American commercial ... (MIGS™) system for spine surgery, the 7D Surgical ... employs cutting-edge 3D optical technologies and machine vision ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... The Masters of Science in ... leaders with decades of experience who remain current practitioners in the field. With ... there is a renewed demand for versatile, data-driven leadership.The American University’s MS in ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... on Crystallization in Process Chemistry by Applying Simple PAT Tools . , ... compounds to isolate and purify the desired product. Chemists now spend more ...
(Date:1/23/2017)... ... 23, 2017 , ... Old School Labs™, makers of the wildly popular all-natural ... Breon Ansley to its growing team of brand ambassadors. The Olympia top finisher and ... less than a year was able to turn professional, participating in the 2013 NPC ...
(Date:1/23/2017)... ... January 23, 2017 , ... “Crossing the Bar”: a moving and eloquent ... life. “Crossing the Bar” is the creation of published author, Charlotte Hotte, a North ... who credits the inspiration of the book to her sister, Denise, wishes to acknowledge ...
(Date:1/23/2017)... ... 23, 2017 , ... Valentine’s Day is a time when many people celebrate romance and love ... may be looking for the ideal present, Atlanta-based Perimeter Plastic Surgery is offering ... free. Or, spend $200 and get $50 free. , “A lot of people just ...
Breaking Medicine News(10 mins):